{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:37:25Z","timestamp":1782977845252,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["22K07462"],"award-info":[{"award-number":["22K07462"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Progn Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is urgent clinical need to identify reliable prognostic biomarkers that predict the progression of dementia symptoms in individuals with early-phase Alzheimer\u2019s disease (AD) especially given the research on and predicted applications of amyloid-beta (A\u03b2)-directed immunotherapies to remove A\u03b2 from the brain. Cross-sectional studies have reported higher levels of cerebrospinal fluid and blood\u00a0glial fibrillary acidic protein (GFAP) in individuals with AD-associated dementia than in cognitively unimpaired individuals. Further, recent longitudinal studies have assessed the prognostic potential of baseline blood GFAP levels as a predictor of future cognitive decline in cognitively unimpaired individuals and in those with mild cognitive impairment (MCI) due to AD. In this systematic review and meta-analysis, we propose analyzing longitudinal studies on blood GFAP levels to predict future cognitive decline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study will include prospective and retrospective cohort studies that assessed blood GFAP levels as a prognostic factor and any prediction models that incorporated blood GFAP levels in cognitively unimpaired individuals or those with MCI. The primary outcome will be conversion to MCI or AD in cognitively unimpaired individuals or conversion to AD in individuals with MCI. Articles from PubMed and Embase will be extracted up to December 31, 2023, without language restrictions. An independent dual screening of abstracts and potentially eligible full-text reports will be conducted. Data will be dual-extracted using the CHeck list for critical appraisal, data extraction for systematic Reviews of prediction Modeling Studies (CHARMS)-prognostic factor, and CHARMS checklists, and we will dual-rate the risk of bias and applicability using the Quality In Prognosis Studies and Prediction Study Risk-of-Bias Assessment tools. We will qualitatively synthesize the study data, participants, index biomarkers, predictive model characteristics, and clinical outcomes. If appropriate, random-effects meta-analyses will be performed to obtain summary estimates. Finally, we will assess the body of evidence using the Grading of Recommendation, Assessment, Development, and Evaluation Approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This systematic review and meta-analysis will comprehensively evaluate and synthesize existing evidence on blood GFAP levels for prognosticating presymptomatic individuals and those with MCI to help advance risk-stratified treatment strategies for early-phase AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>PROSPERO CRD42023481200.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41512-024-00167-3","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:02:13Z","timestamp":1709596933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Blood levels of glial fibrillary acidic protein for predicting clinical progression to Alzheimer\u2019s disease in adults without dementia: a systematic review and meta-analysis protocol"],"prefix":"10.1186","volume":"8","author":[{"given":"Takashi","family":"Nihashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0975-391X","authenticated-orcid":false,"given":"Teruhiko","family":"Terasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"10284","key":"167_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer\u2019s disease. Lancet. 2021;397(10284):1577\u201390.","journal-title":"Lancet"},{"issue":"4","key":"167_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/alz.13016","volume":"19","author":"Alzheimer\u2019s disease facts and figures","year":"2023","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2023;19(4):1598\u2013695.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"167_CR3","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105\u201325.","journal-title":"Lancet Public Health"},{"issue":"6","key":"167_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484\u201396.","journal-title":"Lancet Neurol"},{"issue":"3","key":"167_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","volume":"2","author":"J Ferrero","year":"2016","unstructured":"Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O\u2019Gorman J, Sevigny J. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2016;2(3):169\u201376.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"167_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"167_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12377","volume":"9","author":"LS Honig","year":"2023","unstructured":"Honig LS, Barakos J, Dhadda S, Kanekiyo M, Reyderman L, Irizarry M, Kramer LD, Swanson CJ, Sabbagh M. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2023;9(1): e12377.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10248","key":"167_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413\u201346.","journal-title":"Lancet"},{"issue":"4","key":"167_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14(4):388\u2013405.","journal-title":"Lancet Neurol"},{"issue":"24","key":"167_CR10","doi-asserted-by":"publisher","first-page":"e2944","DOI":"10.1212\/WNL.0000000000012109","volume":"96","author":"B Bellaver","year":"2021","unstructured":"Bellaver B, Ferrari-Souza JP, Uglione da Ros L, Carter SF, Rodriguez-Vieitez E, Nordberg A, Pellerin L, Rosa-Neto P, Leffa DT, Zimmer ER. Astrocyte biomarkers in Alzheimer disease: a systematic review and meta-analysis. Neurology. 2021;96(24):e2944\u201355.","journal-title":"Neurology."},{"issue":"9","key":"167_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/cells12091309","volume":"12","author":"KY Kim","year":"2023","unstructured":"Kim KY, Shin KY, Chang KA. GFAP as a potential biomarker for Alzheimer\u2019s disease: a systematic review and meta-analysis. Cells. 2023;12(9):1309.","journal-title":"Cells"},{"key":"167_CR12","doi-asserted-by":"publisher","first-page":"102046","DOI":"10.1016\/j.arr.2023.102046","volume":"91","author":"A Gaur","year":"2023","unstructured":"Gaur A, Rivet L, Mah E, Bawa KK, Gallagher D, Herrmann N, Lanct\u00f4t KL. Novel fluid biomarkers for mild cognitive impairment: a systematic review and meta-analysis. Ageing Res Rev. 2023;91:102046.","journal-title":"Ageing Res Rev"},{"issue":"7","key":"167_CR13","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, et al. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2023;29(7):1775\u201381.","journal-title":"Nat Med"},{"issue":"1","key":"167_CR14","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1212\/WNL.0000000000009724","volume":"95","author":"JL Ebenau","year":"2020","unstructured":"Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, van Harten AC, Teunissen CE, Barkhof F, van den Bosch KA, et al. ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project. Neurology. 2020;95(1):e46\u201358.","journal-title":"Neurology"},{"issue":"10","key":"167_CR15","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1002\/alz.13084","volume":"19","author":"BP Imbimbo","year":"2023","unstructured":"Imbimbo BP, Watling M, Imbimbo C, Nistic\u00f2 R. Plasma ATN(I) classification and precision pharmacology in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(10):4729\u201334.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"167_CR16","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, Salloway S, Sperling R, Zetterberg H, Teunissen CE. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"167_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3(5):506\u201319.","journal-title":"Nat Aging"},{"issue":"1","key":"167_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"167_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5595","volume":"346","author":"H Hemingway","year":"2013","unstructured":"Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, Briggs A, Udumyan R, Moons KG, Steyerberg EW, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ. 2013;346: e5595.","journal-title":"BMJ"},{"issue":"2","key":"167_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001380","volume":"10","author":"RD Riley","year":"2013","unstructured":"Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, Malats N, Briggs A, Schroter S, Altman DG, et al. Prognosis research strategy (PROGRESS) 2: prognostic factor research. PLoS Med. 2013;10(2): e1001380.","journal-title":"PLoS Med"},{"issue":"2","key":"167_CR21","doi-asserted-by":"publisher","first-page":"e1001381","DOI":"10.1371\/journal.pmed.1001381","volume":"10","author":"EW Steyerberg","year":"2013","unstructured":"Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, Riley RD, Hemingway H, Altman DG. Prognosis research strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10(2):e1001381.","journal-title":"PLoS Med"},{"key":"167_CR22","doi-asserted-by":"publisher","first-page":"e5793","DOI":"10.1136\/bmj.e5793","volume":"346","author":"AD Hingorani","year":"2013","unstructured":"Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, Schroter S, Sauerbrei W, Altman DG, Hemingway H. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ. 2013;346:e5793.","journal-title":"BMJ"},{"key":"167_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/9781119099369.ch17","volume-title":"Systematic Reviews in Health Research: Meta-Analysis in Context","author":"RD Riley","year":"2022","unstructured":"Riley RD, Moons KGM, Altman DG, Collins GS, Debray TPA. Systematic reviews of prognostic factor studies. In: Egger M, Higgins JPT, Smith GD, editors. Systematic Reviews in Health Research: Meta-Analysis in Context. 3rd ed. Hoboken: Wiley-Blackwell; 2022. p. 324\u201346.","edition":"3"},{"issue":"3","key":"167_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303\u20138.","journal-title":"Arch Neurol"},{"issue":"3","key":"167_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"key":"167_CR26","doi-asserted-by":"crossref","unstructured":"Wallace BC, Small K, Brodley CE, Lau J, Trikalinos TA. Deploying an interactive machine learning system in an evidence-based practice center: abstrackr. Proceedings of the 2nd ACM SIGHIT international health informatics symposium; 2012. p. 819\u201324. Available at https:\/\/www.byronwallace.com\/static\/articles\/wallace_ihi_2011_preprint.pdf. Accessed 14 Feb 2024.","DOI":"10.1145\/2110363.2110464"},{"issue":"10","key":"167_CR27","doi-asserted-by":"publisher","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","volume":"11","author":"KG Moons","year":"2014","unstructured":"Moons KG, de Groot JA, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, Reitsma JB, Collins GS. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med. 2014;11(10):e1001744.","journal-title":"PLoS Med"},{"key":"167_CR28","doi-asserted-by":"publisher","first-page":"k4597","DOI":"10.1136\/bmj.k4597","volume":"364","author":"RD Riley","year":"2019","unstructured":"Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, Hayden J, Collins GS, Debray TPA. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ. 2019;364:k4597.","journal-title":"BMJ"},{"issue":"7","key":"167_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology"},{"issue":"3","key":"167_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"24","key":"167_CR31","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815\u201334.","journal-title":"Stat Med"},{"key":"167_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"issue":"5","key":"167_CR33","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.cct.2008.06.002","volume":"29","author":"TV Perneger","year":"2008","unstructured":"Perneger TV. Estimating the relative hazard by the ratio of logarithms of event-free proportions. Contemp Clin Trials. 2008;29(5):762\u20136.","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"167_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280\u20136.","journal-title":"Ann Intern Med"},{"issue":"1","key":"167_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M18-1376","volume":"170","author":"RF Wolff","year":"2019","unstructured":"Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170(1):51\u20138.","journal-title":"Ann Intern Med"},{"issue":"17","key":"167_CR36","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/sim.1482","volume":"22","author":"G Knapp","year":"2003","unstructured":"Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22(17):2693\u2013710.","journal-title":"Stat Med"},{"issue":"1","key":"167_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","volume":"172","author":"JP Higgins","year":"2009","unstructured":"Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137\u201359.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"1","key":"167_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/jrsm.1319","volume":"10","author":"AA Veroniki","year":"2019","unstructured":"Veroniki AA, Jackson D, Bender R, Kuss O, Langan D, Higgins JPT, Knapp G, Salanti G. Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis. Res Synth Methods. 2019;10(1):23\u201343.","journal-title":"Res Synth Methods"},{"issue":"0 1","key":"167_CR39","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.3233\/JAD-150154","volume":"48 Suppl 1","author":"LA Rabin","year":"2015","unstructured":"Rabin LA, Smart CM, Crane PK, Amariglio RE, Berman LM, Boada M, Buckley RF, Ch\u00e9telat G, Dubois B, Ellis KA, et al. Subjective cognitive decline in older adults: an overview of self-report measures used across 19 international research studies. J Alzheimers Dis. 2015;48 Suppl 1(0 1):S63-86.","journal-title":"J Alzheimers Dis"},{"key":"167_CR40","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, R\u00fccker G, Harbord RM, Schmid CH, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"key":"167_CR41","doi-asserted-by":"publisher","first-page":"h870","DOI":"10.1136\/bmj.h870","volume":"350","author":"A Iorio","year":"2015","unstructured":"Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, McGinn T, Hayden J, Williams K, Shea B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350:h870.","journal-title":"BMJ"},{"key":"167_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","volume":"121","author":"F Foroutan","year":"2020","unstructured":"Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, Vernooij R, Arevalo-Rodriguez I, Munn Z, Roshanov P, et al. GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. J Clin Epidemiol. 2020;121:62\u201370.","journal-title":"J Clin Epidemiol"},{"key":"167_CR43","doi-asserted-by":"publisher","first-page":"e073538","DOI":"10.1136\/bmj-2022-073538","volume":"381","author":"KIE Snell","year":"2023","unstructured":"Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, Reitsma JB, Moons KGM, Collins GS, Riley RD. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538.","journal-title":"BMJ"}],"container-title":["Diagnostic and Prognostic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41512-024-00167-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41512-024-00167-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41512-024-00167-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:04:13Z","timestamp":1709597053000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnprognres.biomedcentral.com\/articles\/10.1186\/s41512-024-00167-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["167"],"URL":"https:\/\/doi.org\/10.1186\/s41512-024-00167-3","relation":{},"ISSN":["2397-7523"],"issn-type":[{"value":"2397-7523","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and consent to participate are not applicable, as this is a systematic review of publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}